Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing
number of patients with cancer. Data suggest that up to 36% of cancer patients may be …

Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

Aims Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI).
Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated …

Background: Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells.
There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among …

Background There is a need for improved methods for detection and risk stratification of
myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain …

Background Myocarditis is a potentially fatal complication of immune checkpoint inhibitor
(ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 …

Abstract Background Immune checkpoint inhibitors (ICIs) are widely used cancer treatments.
There are limited data on the risk for developing venous thromboembolism (VTE) among …

Immune checkpoint inhibitors (ICIs) are a novel treatment option for cancer therapy, which
help direct the immune system to recognize and target cancer cells. ICIs have been shown …

Lung cancer is a major cause of cancer-related mortality worldwide, both in men and
women. The vast majority of patients are diagnosed with non-small-cell lung cancer …